YORK, Pa., Feb. 11, 2013 /PRNewswire/ -- Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS), a U.S. based designer, developer and supplier of injectable drug delivery systems, today announced it will exhibit at the Pharmapack Europe Annual Meeting in Paris, France between February 13th and 14th.
“Unilife is delighted to be attending Pharmapack Europe in Paris this week in association with more than 3,000 other pharmaceutical and drug delivery industry leaders,” stated Mr. Michael Ratigan, Senior Vice President and Chief Commercial Officer at Unilife. “The Unilife commercial development team will be available throughout Pharmapack to speak with pharmaceutical companies about how our broad portfolio of innovative and highly differentiated device technologies can be leveraged to enable and enhance their injectable therapies,” Mr. Ratigan said.
In late-2012, Unilife expanded its commercial development team with the appointment of Douglas Stout, Derek Giersch, Joseph Crusco as Senior Directors of Commercial Development, and Jashin Gugnani as Director of Commercial Development.
To support accelerating customer demand, this week Unilife has further expanded its commercial team of world-class industry experts with the appointment of Glenn Thorpe to the position of Vice-President of Commercial Development. Mr. Thorpe joins Unilife from West Pharmaceutical Systems where he was previously Vice-President of Strategic Market Development and Vice-President and General Manager for Injection Systems. Prior to West, Mr. Glenn was at BD Pharmaceutical Systems, where he held various commercial roles with increasing levels of responsibility over a decade.
“We are delighted to welcome Glenn to Unilife’s commercial development team,” said Unilife’s Chief Executive Officer, Alan Shortall. “Glenn has been serving the injectable drug delivery needs of pharmaceutical companies for more than 16 years across a variety of senior roles in sales, business development and strategic marketing. With his deep technical knowledge in the design, development and commercial supply of prefilled syringes, needlestick safety products and patient-self-administration systems, we believe Glenn is a great addition to our world-class team. We look forward to having Glenn make a successful debut for Unilife at Pharmapack Europe,” Mr. Shortall concluded.
Unilife is located at booth 168 during Pharmapack Europe. To schedule an appointment, please contact a member of the Unilife team or email customer.service@unilife.com.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, bolus injection devices and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
General: UNIS-G
Investor Contacts (US): | Analyst Enquiries | Investor Contacts (Australia) | Media Contact |
Todd Fromer / Garth Russell | Lynn Pieper | Jeff Carter | Eve McGrath |
KCSA Strategic Communications | Westwicke Partners | Unilife Corporation | Rubenstein PR |
P: + 1 212-682-6300 | P: + 1 415-202-5678 | P: + 61 2 8346 6500 | P: + 1 212 843-8490 |
SOURCE Unilife Corporation
